

09/586, 937

FILE 'HOME' ENTERED AT 12:39:41 ON 20 SEP 2002

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 12:40:06 ON 20 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 12:40:06 ON 20 SEP 2002

FILE 'CAPLUS' ENTERED AT 12:40:06 ON 20 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:40:06 ON 20 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 12:40:06 ON 20 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s hydrogel network?
L1 252 HYDROGEL NETWORK?

=> s l1 and cross link?
L2 83 L1 AND CROSS LINK?

=> s l2 and (drug? or pharmaceutical?)
L3 36 L2 AND (DRUG? OR PHARMACEUTICAL?)

=> s l3 and precursor?
L4 10 L3 AND PRECURSOR?

=> s l4 and swell
L5 5 L4 AND SWELL

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 5 DUP REM L5 (0 DUPLICATES REMOVED)

=> s l6 and (thiol? or amine?)
L7 5 L6 AND (THIOL? OR AMINE?)

=> d l7 bib abs 1-5

L7 ANSWER 1 OF 5 USPATFULL
AN 2002:213403 USPATFULL
TI Crosslinking agents and methods of use
IN Pathak, Chandrashekhar P., Austin, TX, UNITED STATES
PA Incept LLC (U.S. corporation)
PI US 2002114775 A1 20020822
AI US 2002-68807 A1 20020205 (10)
RLI Division of Ser. No. US 1999-147897, filed on 30 Aug 1999, PENDING
PRAI WO 1997-US16897 19970922
US 1997-40417P 19970313 (60)
US 1997-39904P 19970304 (60)
US 1996-26536P 19960923 (60)

DT Utility
FS APPLICATION
LREP Patterson, Thunte,, Skaar & Christensen, P.A., 4800 IDS Center, 80
South 8th Street, Minneapolis, MN, 55402-2100
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for preparing protein concentrates from protein comprising aqueous compositions. In the subject methods, an initial protein comprising aqueous compositions, such as whole blood or a derivative thereof, is contacted with a non-protein denaturant hydrogel under conditions sufficient for a substantial amount of water present in the composition to be absorbed by the hydrogel, resulting in the production of a protein concentrate, such as a fibrinogen rich composition. Of particular interest is the use of the subject methods to prepare fibrinogen rich compositions, where such compositions produced according to the subject invention are useful in fibrin sealants, **drug** delivery vehicles and in a number of other diverse applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 5 USPATFULL
AN 2002:58865 USPATFULL
TI Mannitol/hydrogel cap for tissue-insertable connections
IN Ley, Gregory R., New Brighton, MN, United States
Hum, Larry L., Cottage Grove, MN, United States
PA Cardiac Pacemakers, Inc., St. Paul, MN, United States (U.S. corporation)
PI US 6360129 B1 20020319
AI US 1999-459782 19991213 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bockelman, Mark
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1058
AB A helical element for insertion into tissue comprises a helical element having an insertion end, a protruding end and an open central area within the wire, rods, filaments, cables or the like that form the helix. The helical element has at least its insertion end covered by a cap of a water-soluble or water-dispersible composition. The composition of the cap comprises a water-soluble or water dispersible component having a hydrogel mixed therein. In one embodiment, there is either a hollow area within the composition within the open central area or the material is more porous than the remaining material. The helical element preferably comprises an electrical lead, such as a positive endocardial lead, with an electrode at the protruding or distal end of the lead.

The helical element may comprise any biocompatible material with sufficient structural integrity to provide a secure attachment to tissue in a patient. Where the helical element is also to provide an active (electrically active) function, the composition of the helical element should also be electrically conductive.

L7 ANSWER 3 OF 5 USPATFULL
AN 1999:166624 USPATFULL
TI Protein-containing polymer composition for oral administration
IN Plate, Nikolai A., Moscow, Russian Federation
Valuev, Lev I., Moscow, Russian Federation

Valueva, Tatyana A., Moscow, Russian Federation
 Staroseltseva, Ludmila K., Moscow, Russian Federation
 Ametov, Alexander S., Moscow, Russian Federation
 Knyazhev, Vladimir A., Moscow, Russian Federation
 Henis, Jay M.S., St. Louis, MO, United States
 PA Orex Pharmaceutical Development Corp., St. Louis, MO, United States
 (U.S. corporation)
 PI US 6004583 19991221
 AI US 1996-691617 19960802 (8)
 RLI Continuation-in-part of Ser. No. US 1995-408076, filed on 22 Mar 1995
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Webman, Edward J.
 LREP Shust, Nestor W. Hudak & Shunk Co., L.P.A.
 CLMN Number of Claims: 69
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic-containing composition adapted for the oral administration of a biologically active material which comprises a water insoluble but water swellable polymer chemically modified with an enzyme inhibitor containing a chemical functionality which has an interactive affinity for target receptors located on the transport barrier walls of the digestive tract of the intended recipient, and at least one therapeutic of low oral bioavailability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 5 USPATFULL
 AN 1999:102846 USPATFULL
 TI Process for preparing biologically compatible polymers and their use in medical devices
 IN Plate, Nicolai A., Moscow, Russian Federation
 Valuev, Lev I., Moscow, Russian Federation
 Uzhinova, Lubov D., Moscow, Russian Federation
 Sinani, Vladimir A., Moscow, Russian Federation
 PA A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Science, Moscow, Russian Federation (non-U.S. corporation)
 PI US 5945457 19990831
 AI US 1997-942571 19971001 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Krass, Frederick
 LREP Hudak & Shunk Co., L.P.A., Shust, Nestor W.
 CLMN Number of Claims: 33
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1694

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hemocompatible composition comprising a polymer containing at least one pharmacologic material chemically bonded to a polymer backbone. Such compositions may be obtained by reacting a pharmacologic material with a compound containing a polymerizable group (e.g., an acyl halide) and thereafter either copolymerizing the acylated material with one or more copolymerizable monomers or first irradiating a backbone polymer and thereafter grafting the acylated pharmacologic material onto the irradiated polymer. The resulting products are hemocompatible and may be used in the manufacture of medical devices which come in contact with blood or other bodily fluids. The advantage of chemically bonded pharmacologic materials is that they are not leached out and retain their **pharmaceutical** effectiveness for a long period of time. The compositions may contain one or more additional pharmacologic materials which are physically admixed with polymers containing bonded

pharmacologic materials.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 5 USPATFULL
AN 84:28595 USPATFULL
TI Simultaneous delivery of two **drugs** from unit delivery device
IN Cortese, Richard, San Jose, CA, United States
Barclay, Brian, Menlo Park, CA, United States
Theeuwes, Felix, Los Altos, CA, United States
PA ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 4449983 19840522
AI US 1982-360589 19820322 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Padgett, Benjamin R.; Assistant Examiner: Wallen, T.
J.
LREP Sabatine, Paul L., Mandell, Edward L., Stone, Steven F.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1050

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An osmotic device is disclosed for delivering two beneficial **drugs** to an environment of use. The device comprises a wall surrounding a lumen divided into a first compartment containing a **drug** that is separated by a hydrogel partition from a second compartment containing a different **drug**. An orifice through the wall communicates with the first compartment for delivering **drug** formulation from the first compartment, and another orifice through the wall communicates with the second compartment for delivering **drug** formulation from the second compartment. In operation, **drug** formulation is dispensed separately from each compartment by fluid being imbibed through the wall into each compartment at a rate controlled by the permeability of the wall and the osmotic pressure gradient across the wall against the **drug** formulation in each compartment thereby producing in each compartment a solution containing **drugs**, and by the expansion and swelling of the hydrogel, whereby **drug** formulation is dispensed through their orifices at a controlled and continuous rate over a prolonged period of time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.